Showing results (21-30 of 74) with videos related to

Sort By:
Pageof 8
Dermatology Reports|October 4, 2023
Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative studyAndrea Cortese, Luigi Gargiulo, Luciano Ibba, et al.
Journal of Clinical Medicine|May 14, 2025
Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective StudyLuciano Ibba, Costanza Falcidia, Sara Di Giulio, et al.
Journal of Clinical Medicine|October 29, 2025
Real-Life Effectiveness and Safety of Bimekizumab in Plaque Psoriasis Involving Difficult-to-Treat Areas: A 52-Week, Retrospective Real-World, Single-Center StudyMatteo Bianco, Francesco D'Oria, Gioele Ghezzi, et al.
International Journal of Dermatology|March 5, 2021
Impact of delay in follow-up due to COVID-19 pandemic on skin cancer progression: a real-life experience from an Italian hub hospitalMario Valenti, Giulia Pavia, Luigi Gargiulo, et al.
Journal of Drugs in Dermatology : JDD|August 2, 2024
Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center StudyLuigi Gargiulo, Luciano Ibba, Andrea Cortese, et al.
Dermatology and Therapy|September 5, 2022
Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective StudyLuigi Gargiulo, Luciano Ibba, Giulia Pavia, et al.
International Journal of STD & AIDS|September 11, 2023
Effectiveness and safety of risankizumab in HIV patients with psoriasis: A case seriesDiego Orsini, Fabio S Maramao, Luigi Gargiulo, et al.
The Journal of Dermatological Treatment|June 8, 2023
Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centersDiego Orsini, Luigi Gargiulo, Luciano Ibba, et al.
Expert Opinion on Biological Therapy|April 1, 2026
Tildrakizumab in the treatment of moderate-to-severe plaque psoriasis: expert insights from Italian real-world experienceAngelo Ruggiero, Martina Burlando, Anna Balato, et al.
The Journal of Dermatology|January 31, 2024
Effectiveness of ixekizumab for the treatment of moderate-to-severe plaque psoriasis with involvement of difficult-to-treat areas: A 52-week multicenter retrospective studyMario Valenti, Luigi Gargiulo, Luciano Ibba, et al.
Pageof 8